YAHOO FINANCE ELECTION GUIDE What the 2024 campaign means for your wallet NasdaqGM - Nasdaq Real Time Price ? USD SCYNEXIS, Inc. (SCYX) Follow Compare 1.3050 -0.0150 (-1.14%) As of 9:59 AM EST. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years Long term investing works well, but it doesn't always work for each individual stock. We really hate to see fellow... Simply Wall St. ? 6 days ago SCYX -1.14% SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit JERSEY CITY, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, at 11:30 A.M. ET. Maxim Healthcare Virtual Summit Details: Format:Fireside chatDate:Thursday, October 17, GlobeNewswire ? 26 days ago SCYX -1.14% SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024 JERSEY CITY, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations of preclinical efficacy and pharmacokinetic data on its second-generation fungerp candidate SCY-247 at IDWeek 2024 taking place in Los Angeles, CA from October 16-19, 2024. Presentation details can be found below: Oral Presentation: Title:Efficacy GlobeNewswire ? last month SCYX -1.14% SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference JERSEY CITY, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will make a corporate presentation as well as host 1x1 meetings at the H. C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11 at 10:00 A.M. ET. H. C. Wainwright 26th Annual Global I GlobeNewswire ? 2 months ago SCYX -1.14% SCYNEXIS Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags SCYNEXIS ( NASDAQ:SCYX ) Second Quarter 2024 Results Key Financial Results Revenue: US$736.0k (down 99% from 2Q 2023... Simply Wall St. ? 2 months ago SCYX -1.14% Scynexis: Q2 Earnings Snapshot JERSEY CITY, N.J. (AP) — Scynexis Inc. SCYX) on Thursday reported a loss of $14.5 million in its second quarter. The Jersey City, New Jersey-based company said it had a loss of 30 cents per share. Associated Press Finance ? 2 months ago SCYX -1.14% SCYNEXIS Reports Second Quarter 2024 Financial Results?and Provides Corporate Update Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to SCYNEXIS which we expect to receive in Q3 2024. SCY-247’s IND-enabling activities continue to progress. Pre-clinical in vitro and in vivo studies, presented at several medical conferences, have shown potent and broad antifungal activity. Phase 1 study initiation is planned for Q4 2024. SCYNEXIS ended Q2 GlobeNewswire ? 2 months ago SCYX -1.14% SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports Reiterating cash runway of > 2 yearsJERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment under its exclusive license agreement with GSK for ibrexafungerp. The milestone payment is triggered by the delivery of final clinical study reports for the completed FU GlobeNewswire ? 3 months ago SCYX -1.14% 3 Stocks Under $10 With the Potential for Massive Gains Investing in small-cap stocks can be a gateway to high returns, mainly when these companies exhibit strong growth fundamentals and strategic market positioning. Here, the focus is on three stocks to buy under $10. The fundamentals behind these companies may diversify portfolios with high potential. These companies’ financial performance and strategic initiatives explain why these small-cap stocks are poised for high gains. The first one has consistently demonstrated impressive top-line growth, d InvestorPlace ? 3 months ago SOFI INGN SCYX -1.14% Hidden Gems: 3 Under-$10 Stocks Poised for 500% Growth by 2025 The ability to recognize possibilities while investing can frequently be the difference between stagnation and growth in an unstable and changing economic environment. Here are three exciting stocks in technology, insurance, and medicines. Leading the pack among these chances is the first, which has cleverly turned to utilize partnerships and licensing agreements to generate income. These tactical changes highlight a practical reaction to the difficulties and expenses of medicine marketing, even InvestorPlace ? 5 months ago IMMR HRTG SCYX -1.14% 3 Stocks Under $10 With Mammoth Growth Prospects Finding good prospects is like hunting gold in the fast-paced world of investing. Three stocks stand out in this hunt, all under $10, with significant growth potential. These companies operate in a variety of industries, including technology and healthcare. They offer a unique opportunity to profit from rapid revenue growth, strong financial stability and well-thought-out development strategies. With a robust organic revenue increase in the first quarter and a solid focus on the hyaluronic acid InvestorPlace ? 5 months ago BVS IMMR SCYX -1.14% SCYNEXIS Reports First Quarter 2024 Financial Results?and Provides Corporate Update SCY-247’s IND-enabling activities continue to progress, with initiation of Phase I anticipated in the second half of 2024Clinical study reports for the FURI, CARES and NATURE trials in refractory invasive fungal infections remain on track for delivery to GSK in mid 2024, which would trigger a $10 million development milestone payment to SCYNEXISSCYNEXIS ended Q1 2024 with cash, cash equivalents and investments of $94.2 million and projects a cash runway of more than two years JERSEY CITY, N.J., GlobeNewswire ? 5 months ago SCYX -1.14% Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 87% over the last five years Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish... Simply Wall St. ? 5 months ago SCYX -1.14% SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID) In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrataSCY-247 showed in vitro activity against a broad range of pathogenic fungi, including azole-resistant strains of Candida and Aspergillus species JERSEY CITY, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentat GlobeNewswire ? 6 months ago SCYX -1.14% SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-generation fungerp candidate SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain from April 27-30, 2024. SCY-247 is being developed to address sy GlobeNewswire ? 6 months ago SCYX -1.14% SCYNEXIS Reports Full Year 2023 Financial Results?and Provides Corporate Update SCY-247’s IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 Data analysis for the FURI study is ongoing; top line data from the CARES study has been received and is positive and consistent with previously disclosed results from interim analyses The clinical study reports for FURI, CARES and NATURE in refractory invasive fungal infections are on target for delivery to GSK in the first half of 2024 which would trigger a $10 million develo GlobeNewswire ? 7 months ago SCYX -1.14% SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference JERSEY CITY, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will present at Guggenheim’s 6th Annual Biotechnology Conference on Wednesday, February 7 at 11:00 A.M. ET. Guggenheim’s 6th Annual Biotechnology Conference Format: Fireside chat and one-on-one meetingsDate: Wed GlobeNewswire ? 9 months ago SCYX -1.14% SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference In vivo data demonstrated response rate for oral SCY-247 similar to current standard of care, intravenous Liposomal Amphotericin B, for the treatment of mucormycosisCombination of SCY-247 and Liposomal Amphotericin B showed significant enhancement in survival and reduction in fungal burden in lung and brain tissue compared to monotherapies JERSEY CITY, N.J., Jan. 29, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and pr GlobeNewswire ? 9 months ago SCYX -1.14% SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy JERSEY CITY, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second generation fungerp candidate SCY-247 for the treatment of mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis (AAAM) Conference in Milan, Italy from January 25 – 27, 2024. Poster Presentati GlobeNewswire ? 9 months ago SCYX -1.14% Shareholders in SCYNEXIS (NASDAQ:SCYX) are in the red if they invested five years ago We're definitely into long term investing, but some companies are simply bad investments over any time frame. It hits... Simply Wall St. ? 11 months ago SCYX -1.14% Performance Overview Trailing total returns as of 11/5/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return SCYX S&P 500 YTD -41.48% +20.68% 1-Year -30.59% +32.07% 3-Year -76.27% +22.99%
